Target intelligence / Profile preview

Neisseria meningitidis group Y capsular polysaccharide (MenY-PS)

Target
MenY-PS
Molecular classification
Bacterial capsular polysaccharide, Antigen, Other
01

Overview

The capsular polysaccharide of Neisseria meningitidis group Y is a major virulence factor and cell-surface antigen of the Gram-negative bacterium Neisseria meningitidis serogroup Y. Structurally, it is a partially O-acetylated copolymer composed of alternating units of N-acetylneuraminic acid (sialic acid) and D-glucose. This polysaccharide capsule plays a critical role in bacterial survival within the host by preventing opsonization and inhibiting complement-mediated phagocytosis, allowing the pathogen to evade the host's immune system. Neisseria meningitidis serogroup Y is a significant cause of invasive meningococcal disease, which can manifest as life-threatening meningitis, septicemia (meningococcemia), and pneumonia. As a therapeutic target, this capsular polysaccharide is utilized as an antigen in several meningococcal vaccines to stimulate active immunity. To overcome the poor immunogenicity of pure polysaccharides in infants and young children, the polysaccharide is typically conjugated to carrier proteins such as diphtheria toxoid, CRM197, or tetanus toxoid. Vaccination induces the production of serogroup-specific bactericidal antibodies that activate the classical complement pathway, leading to complement-mediated lysis and phagocytosis of the bacteria. Prominent vaccines targeting this antigen include Menactra, Menveo, Nimenrix, MenQuadfi, and the pentavalent vaccine Penbraya.

Other names
Neisseria meningitidis group Y capsular polysaccharide antigenMeningococcal polysaccharide antigen group YMeningococcal group Y capsular polysaccharideGroup Y meningococcal polysaccharideGYMPPS-Y
02

Mechanism of action

Active immunization. The capsular polysaccharide acts as an antigen that, when administered (often conjugated to a carrier protein to enhance T-cell dependent response), stimulates the host immune system to produce serogroup-specific bactericidal antibodies (IgG and IgM). These antibodies, in cooperation with the complement system, mediate complement-dependent bactericidal killing and opsonophagocytosis of Neisseria meningitidis serogroup Y bacteria, thereby preventing invasive meningococcal disease.

03

Biological functions

Immune responseBacterial virulenceOther
04

Disease associations

Infection
05

Safety considerations

Injection site reactions (pain, redness, swelling)Systemic adverse events (headache, fatigue, irritability, fever, myalgia)Hypersensitivity or anaphylaxisGuillain-Barre syndrome (GBS)Reduced immunogenicity in immunocompromised individualsPersistent risk of invasive disease in individuals with complement deficiencies or those receiving complement inhibitors (such as eculizumab)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Serum bactericidal antibody (SBA) titerrSBA (rabbit complement serum bactericidal activity) titerhSBA (human complement serum bactericidal activity) titerSerogroup Y-specific IgG antibody level

Beyond the preview

Go deeper on Neisseria meningitidis group Y capsular polysaccharide (MenY-PS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis group Y capsular polysaccharide (MenY-PS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call